Clinical Trials on MSI-H/dMMR Tumors

Total 83 results

BeiGene

Recruiting

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors

China
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

MSI-H/dMMR Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

MSI-H or dMMR Advanced Solid Tumors

China
Peking University Cancer Hospital & Institute

Recruiting

Registry Study in MSI/dMMR Solid Tumors

Solid Tumor | MSI-H | DMMR Cancer

China
Servier Bio-Innovation LLC
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier

Not yet recruiting

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer
University of Utah
Elevar Therapeutics

Terminated

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (APPEASE)

Urothelial Carcinoma | Advanced Malignancies | Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | MSI-H or dMMR Solid Tumors

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | MSI-H Tumors

United States
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

MSI-H Solid Malignant Tumor

China
Yonsei University
Merck KGaA, Darmstadt, Germany

Active, not recruiting

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

PD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation Tumor

Korea, Republic of
Sun Yat-sen University

Recruiting

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

DMMR Colorectal Cancer | MSI-H Colorectal Cancer | Locally Advanced Colorectal Cancer

China
Ibrahim Halil Sahin
GlaxoSmithKline

Not yet recruiting

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

MMR-D/MSI-H Colorectal Cancers

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI)

MSI | dMMR Colorectal Cancer

France
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer (PICC)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
University Medical Center Groningen

Recruiting

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN)

Melanoma | Head and Neck Neoplasms | MSI-H Cancer

Netherlands
Sun Yat-sen University

Recruiting

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
West China Hospital
First Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaborators

Recruiting

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr Deficiency

China
Peking University

Not yet recruiting

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Centre Leon Berard

Active, not recruiting

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP)

Localized Resectable Tumor | MSI/dMMR or EBV-positive Gastric Cancers

France
Sun Yat-sen University

Recruiting

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Colorectal Cancer Stage II | Colorectal Cancer Stage III | MSI-H | Mmr Deficiency

China
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA)

Localized Oesogastric Adenocarcimona | MSI and or dMMR

France
Eli Lilly and Company

Active, not recruiting

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

Pancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)

France, Spain, Belgium, Korea, Republic of, United States, Taiwan, Canada
Zhejiang University

Recruiting

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

MSS | Locally Advanced Rectal Carcinoma | pMMR | MSI-L

China
Albert Einstein College of Medicine

Terminated

Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Cancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid Cancer

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
The Netherlands Cancer Institute
Agenus Inc.

Recruiting

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

Resectable MMR-deficient Solid Tumors | Resectable MMR-proficient Solid Tumors

Netherlands
Shen Lin

Not yet recruiting

An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors

To Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal Cancer

China
Centre Leon Berard
Agenus Inc.

Not yet recruiting

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME)

Gastric Cancer | Metastatic Cancer | Advanced Cancer | MSI-H

France
Fudan University

Not yet recruiting

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Gastric Cancer | MSI-H | Adjuvant Therapy | PD-1 Immunotherapy

China
University of Campania "Luigi Vanvitelli"

Completed

Predictive Value of DNA Mismatch Repair System in Colorectal Cancers (DNAMMR)

MSI-H Colorectal Cancer
ImmuneOncia Therapeutics Inc.

Not yet recruiting

A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)

TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
Ibrahim Halil Sahin
Bayer

Not yet recruiting

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

MSI-H Colorectal Cancer

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Colon Cancer | Immunotherapy | MSI-H | Adjuvant Therapy

China
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Capecitabine | MSI-H Colorectal Cancer | Oxaliplatin | Tislelizumab
Apexigen America, Inc.

Completed

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Melanoma | Cancer | Head and Neck Cancer | NSCLC | Urothelial Carcinoma | MSI-H

United States
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb

Active, not recruiting

Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT)

Neuroendocrine Tumors | Advanced Biliary Tract Cancer | Female Reproductive System Neoplasm | MSI-H Solid Malignant Tumor

New Zealand, Australia
Tianjin Medical University Cancer Institute and...

Recruiting

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

MSI-H Advanced Colorectal Cancer

China
China Medical University, China

Recruiting

Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Metastatic Colorectal Adenocarcinoma | MSS | pMMR

China
Incyte Corporation

Recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)

United States, Japan, France, Belgium, Australia
Astellas Pharma Global Development, Inc.

Completed

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Advanced Solid Tumors | Pharmacokinetics of 14C-OSI-906

United States
University of Zurich

Terminated

PET/MRI Perfusion and CT Perfusion in Solid Tumors (Perfusion)

CT Perfusion and MRI Perfusion in Solid Tumors

Switzerland
Incyte Corporation

Recruiting

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Melanoma | Hepatocellular Carcinoma (HCC) | Renal Cell Carcinoma (RCC) | Colorectal Carcinoma (CRC) | Microsatellite Instability - High (MSI-H) | Mismatch Repair Deficient (dMMR)

United States, Brazil, Canada, Australia, Mexico, Slovakia, Sweden, Norway
Second Affiliated Hospital, School of Medicine,...
Shanghai Junshi Bioscience Co., Ltd.; Qilu Pharmaceutical Co., Ltd.

Unknown

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (BEVTOR)

MSS | pMMR | Refractory Metastatic Colorectal Cancer

China
Universitaire Ziekenhuizen KU Leuven

Unknown

Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Gastro-intestinal Tumors (s51240)

Non-invasive | Gastro-intestinal Tumor | Accurate Staging | Whole-body Diffusion Weighted MRI

Belgium
Replimune Inc.
Roche Pharma AG

Active, not recruiting

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

MSS | pMMR | Refractory Metastatic Colorectal Cancer

United States
University Hospital, Clermont-Ferrand

Not yet recruiting

Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis (IRMAA)

MRI | Diagnosis | Invasion | Urinary Bladder Tumour

France
Federation Francophone de Cancerologie Digestive

Recruiting

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI)

Metastatic Colorectal Cancer | MSS | pMMR | Immune Checkpoint Inhibitor | Internal Radiotherapy

France

Clinical Trials on MSI-H/dMMR Tumors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations